SCHEMBL18375950

SCHEMBL18375950

CCOC(=O)c1ccc(NC(=O)c2ccccc2NC(=O)c2ccccc2Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
GAA P10253 3/20 0.67
RAB9A P51151 3/20 0.67
NPC1 O15118 2/20 0.67
ACR P10323 1/20 0.59
MAPT P10636 3/20 0.56
MAPK1 P28482 2/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 3/20 0.55
LMNA P02545 2/20 0.55
SMO Q99835 1/20 0.54
TSHR P16473 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TP53 P04637 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14855964 0.88 SMN1; SMN2 (0.80) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL8319324 0.83 RAB9A (0.64) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL28665987 0.81 SMN1; SMN2 (0.76) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL5232976 0.81 SMN1; SMN2 (1.00) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL2011651 0.81 RAB9A (0.77) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4122902 0.80 TRPV1 (0.65) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL14855798 0.80 SMN1; SMN2 (0.75) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL7209259 0.79 LMNA (0.67) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL30539412 0.79 ALDH1A1 (0.76) ALDH1A1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL9645988 0.79 RAB9A (0.57) ALDH1A1MEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007589-A1 Compositions For Treating Retinal Degeneration And Methods of Production and Use Thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170007589-A1 Compositions For Treating Retinal Degeneration And Methods of Production and Use Thereof ALDH1A2, PDE6D, PDE6H ALDH1A1 465/4885MEN1 4711/4885KMT2A 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.